Lipidomic signature of stroke recurrence after transient ischemic attack

Purroy, F.; Ois, A.; Jove, M.; Arque, G.; Sol, J.; Mauri-Capdevila, G.; Rodriguez-Campello, A.; Pamplona, R.; Portero, M.; Roquer, J.

doi:10.1038/s41598-023-40838-7

Cited by 3 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, triacylglycerol species (TG [48:1] and [48:2], VIP > 2; TG [50:3], [53:3] and [56:6], VIP > 1.5, Figure 1b) were significantly decreased in patient serums compared to control serums (Figures 2 and 3), while TG (52:4) and TG (54:3) (VIP > 1.5, Figure 4b) were decreased in stroke thrombi compared to patient serums (Figures 5 and 6). This is in accordance with previous studies, characterizing TG as bioenergetic compounds of lipid droplets that are also present in neural cells, which were reported to have low abundance in plasma patients having stroke recurrence after transient ischemic attack, possibly due to low accumulation or formation of cerebral lipid droplets as a product of a defective ischemia-associated stress response [48].…”

Section: Discussionsupporting

confidence: 93%

Comparative Targeted Metabolomics in Ischemic Stroke Patients: Profiling Thrombi and Serums Samples for Identification of Stroke-related Metabolites

Karmelić,

Rubić,

Starčević

et al. 2024

Preprint

View full text Add to dashboard Cite

Ischemic stroke is one of the leading causes of death and permanent disability in the world. Rapid diagnosis and intervention are crucial for reducing its consequences on individuals and societies. Identifying reliable biomarkers for early detection, prognostics and therapy is a criti-cal imperative for improving the stroke patient treatment. Metabolomics has been shown as a promising tool for biomarker discovery since many of the post-ischemic metabolites can found in the plasma or serum of the patient. In this research, we have performed comparative targeted metabolomic analysis of stroke thrombi, patient serums and healthy control serums in order to determine the alteration in the patients’ metabolome. The most statistically altered metabolites characterized in patient compared to control serums were glutamate and serotonin, followed by several lipid metabolites (phospholipids and triacylglycerols) and glucose. In stroke thrombi compared to patient’s serums, the most significantly altered metabolites were classified as li-pids, with choline-containing phospholipids and sphingomyelins having the highest discrimi-natory score. The results of this study could help in understanding the roles of different meta-bolic changes occurring during thrombosis and cerebral ischemia and possibly suggest new metabolic biomarkers of the ischemic stroke.

show abstract

Section: Discussionsupporting

confidence: 93%

Comparative Targeted Metabolomics in Ischemic Stroke Patients: Profiling Thrombi and Serums Samples for Identification of Stroke-related Metabolites

Karmelić,

Rubić,

Starčević

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Phosphatidyl-cholines are components of plasma lipoproteins regulating circulating lipoprotein levels such as low-density (VLDLs) and high density (HDL) lipoproteins 113 . Consequently, several studies demonstrated phosphatidyl-cholines related to a decreased risk for diabetes, cardiovascular disease and stroke [ 119 – 121 ]. Triacylglycerides …”

Section: Ongoing 3pm Research Towards Vulnerable Groups In the Popula...mentioning

confidence: 99%

“…Consistent with this data, an association between hypertriglyceridemia in diabetic patients and lower-extremity amputation risk has been shown [ 122 ]; blood triglycerides have been demonstrated as reliable pre/diabetes biomarkers [ 123 ]. In parallel, specific lipid profiles were demonstrated to be linked to high-risk for ischemic stroke [ 121 ].…”

Section: Ongoing 3pm Research Towards Vulnerable Groups In the Popula...mentioning

confidence: 99%

The paradigm change from reactive medical services to 3PM in ischemic stroke: a holistic approach utilising tear fluid multi-omics, mitochondria as a vital biosensor and AI-based multi-professional data interpretation

Golubnitschaja,

Polivka,

Potuznik

et al. 2024

EPMA Journal

View full text Add to dashboard Cite

Worldwide stroke is the second leading cause of death and the third leading cause of death and disability combined. The estimated global economic burden by stroke is over US$891 billion per year. Within three decades (1990–2019), the incidence increased by 70%, deaths by 43%, prevalence by 102%, and DALYs by 143%. Of over 100 million people affected by stroke, about 76% are ischemic stroke (IS) patients recorded worldwide. Contextually, ischemic stroke moves into particular focus of multi-professional groups including researchers, healthcare industry, economists, and policy-makers. Risk factors of ischemic stroke demonstrate sufficient space for cost-effective prevention interventions in primary (suboptimal health) and secondary (clinically manifested collateral disorders contributing to stroke risks) care. These risks are interrelated. For example, sedentary lifestyle and toxic environment both cause mitochondrial stress, systemic low-grade inflammation and accelerated ageing; inflammageing is a low-grade inflammation associated with accelerated ageing and poor stroke outcomes. Stress overload, decreased mitochondrial bioenergetics and hypomagnesaemia are associated with systemic vasospasm and ischemic lesions in heart and brain of all age groups including teenagers. Imbalanced dietary patterns poor in folate but rich in red and processed meat, refined grains, and sugary beverages are associated with hyperhomocysteinaemia, systemic inflammation, small vessel disease, and increased IS risks. Ongoing 3PM research towards vulnerable groups in the population promoted by the European Association for Predictive, Preventive and Personalised Medicine (EPMA) demonstrates promising results for the holistic patient-friendly non-invasive approach utilising tear fluid-based health risk assessment, mitochondria as a vital biosensor and AI-based multi-professional data interpretation as reported here by the EPMA expert group. Collected data demonstrate that IS-relevant risks and corresponding molecular pathways are interrelated. For examples, there is an evident overlap between molecular patterns involved in IS and diabetic retinopathy as an early indicator of IS risk in diabetic patients. Just to exemplify some of them such as the 5-aminolevulinic acid/pathway, which are also characteristic for an altered mitophagy patterns, insomnia, stress regulation and modulation of microbiota-gut-brain crosstalk. Further, ceramides are considered mediators of oxidative stress and inflammation in cardiometabolic disease, negatively affecting mitochondrial respiratory chain function and fission/fusion activity, altered sleep–wake behaviour, vascular stiffness and remodelling. Xanthine/pathway regulation is involved in mitochondrial homeostasis and stress-driven anxiety-like behaviour as well as molecular mechanisms of arterial stiffness. In order to assess individual health risks, an application of machine learning (AI tool) is essential for an accurate data interpretation performed by the multiparametric analysis. Aspects presented in the paper include the needs of young populations and elderly, personalised risk assessment in primary and secondary care, cost-efficacy, application of innovative technologies and screening programmes, advanced education measures for professionals and general population—all are essential pillars for the paradigm change from reactive medical services to 3PM in the overall IS management promoted by the EPMA.

show abstract

Comparative Targeted Metabolomics of Ischemic Stroke: Thrombi and Serum Profiling for the Identification of Stroke-Related Metabolites

Karmelić,

Rubić,

Starčević

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Ischemic stroke is one of the leading causes of death and permanent disability in the world. Rapid diagnosis and intervention are crucial for reducing its consequences on individuals and societies. Therefore, identifying reliable biomarkers for early detection, prognostics, and therapy can facilitate the early prediction and prevention of stroke. Metabolomics has been shown as a promising tool for biomarker discovery since many post-ischemic metabolites can be found in the plasma or serum of the patient. In this research, we performed a comparative targeted metabolomic analysis of stroke thrombi, stroke patient serums, and healthy control serums in order to determine the alteration in the patients’ metabolomes, which might serve as biomarkers for early prediction or stroke prevention. The most statistically altered metabolites characterized in the patient serums compared with the control serums were glutamate and serotonin, followed by phospholipids and triacylglycerols. In stroke thrombi compared with the patients’ serums, the most significantly altered metabolites were classified as lipids, with choline-containing phospholipids and sphingomyelins having the highest discriminatory score. The results of this preliminary study could help in understanding the roles of different metabolic changes that occur during thrombosis and cerebral ischemia and possibly suggest new metabolic biomarkers for ischemic stroke.

show abstract

Lipidomic signature of stroke recurrence after transient ischemic attack

Cited by 3 publications

References 47 publications

Comparative Targeted Metabolomics in Ischemic Stroke Patients: Profiling Thrombi and Serums Samples for Identification of Stroke-related Metabolites

Comparative Targeted Metabolomics in Ischemic Stroke Patients: Profiling Thrombi and Serums Samples for Identification of Stroke-related Metabolites

The paradigm change from reactive medical services to 3PM in ischemic stroke: a holistic approach utilising tear fluid multi-omics, mitochondria as a vital biosensor and AI-based multi-professional data interpretation

Comparative Targeted Metabolomics of Ischemic Stroke: Thrombi and Serum Profiling for the Identification of Stroke-Related Metabolites

Contact Info

Product

Resources

About